Annexon, Inc. (ANNX) NASDAQ
5.21
-0.16(-2.98%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.21
-0.16(-2.98%)
Currency In USD
| Previous Close | 5.37 |
| Open | 5.25 |
| Day High | 5.37 |
| Day Low | 5.06 |
| 52-Week High | 7.18 |
| 52-Week Low | 1.85 |
| Volume | 1.85M |
| Average Volume | 2.53M |
| Market Cap | 623.09M |
| PE | -4.34 |
| EPS | -1.2 |
| Moving Average 50 Days | 5.7 |
| Moving Average 200 Days | 4.4 |
| Change | -0.16 |
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million peopl
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million peopl
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy